10-Q: Keros Therapeutics Reports Q1 2026 Financials

Keros Therapeutics reports a net loss of $23.7 million for Q1 2026, a significant decrease from the prior year's net income, primarily due to the absence of a large upfront licensing payment.

Summary

• Keros Therapeutics reported a net loss of $23.7 million for the first quarter ended March 31, 2026, compared to a net income of $148.5 million in the same period of 2025.
• The decrease in profitability is largely attributed to the absence of a $195.4 million license revenue recognized in Q1 2025 from the Takeda Agreement.
• Total revenue for Q1 2026 was $0.4 million, a substantial decrease from $211.2 million in Q1 2025.
• Research and development expenses decreased to $16.1 million from $48.7 million in the prior year, mainly due to reduced elritercept and cibotercept-related expenses.
• General and administrative expenses remained relatively stable at $10.1 million compared to $10.5 million in the prior year.
• The company had $281.5 million in cash and cash equivalents as of March 31, 2026, and expects this to fund operations into the first half of 2028.
• The company is advancing its product candidates, rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and elritercept (KER-050) for cytopenias.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant net loss and revenue drop compared to the prior year, although the strong cash position provides some stability.

Positives

• The company maintains a strong cash position of $281.5 million as of March 31, 2026, providing runway into the first half of 2028.
• Research and development expenses have decreased significantly, indicating efficient resource allocation or transition of certain activities.
• The company continues to advance its pipeline with rinvatercept and elritercept, with plans for Phase 2 trials in DMD and ALS for rinvatercept.

Negatives

• The company reported a net loss of $23.7 million for the quarter, a significant shift from the prior year's net income.
• Total revenue decreased substantially to $0.4 million from $211.2 million, primarily due to the one-time nature of the Takeda license revenue recognized in the prior year.
• The company has an accumulated deficit of $505.5 million as of March 31, 2026.
• The company expects to continue incurring operating losses and negative operating cash flows in the foreseeable future.

Risks

• The company has a limited operating history and has incurred net losses in almost every year since its inception, with expectations to continue incurring net losses.
• The company will need substantial additional funding to complete the development and commercialization of its product candidates.
• The success of the company is heavily dependent on the success of its product candidates, which are in clinical development.
• Clinical trials are lengthy, expensive, and have uncertain outcomes; delays or failures in these trials could materially harm the business.
• The company relies on third parties for clinical trials and manufacturing, and any failure by these parties could substantially harm the business.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Protecting intellectual property is crucial and costly, with no guarantee of successful protection.
• Public health crises could adversely impact the timing or results of preclinical studies and clinical trials.
• The company's ability to generate revenue depends on the successful development and commercialization of its product candidates, which may never occur.

Future Outlook

The company expects to continue to incur operating losses and negative operating cash flows in the foreseeable future. Its existing cash and cash equivalents are expected to fund operations into the first half of 2028. Future funding will depend on various factors including the progress of clinical trials, milestone payments, and potential collaborations.

Management Comments

• Management believes that the Company's existing cash and cash equivalents as of March 31, 2026 will allow the Company to continue its operations for at least the next 12 months.
• In the absence of a significant source of recurring revenue, the continued viability of the Company is dependent on its ability to continue to raise additional capital to finance its operations.
• We expect research and development expenses to continue to increase for the foreseeable future, with the exception of elritercept-related expenses which are expected to decrease once transitioned to Takeda, as we continue ongoing and initiate new clinical trials for our product candidates and continue to discover and develop additional product candidates.

Industry Context

StockSavvy.ai notes that Keros Therapeutics operates in the highly competitive clinical-stage biopharmaceutical sector, focusing on TGF-beta signaling pathways. The company's financial performance is heavily influenced by the success of its drug candidates in clinical trials and its ability to secure partnerships and funding, common challenges for companies at this stage.

Comparison to Industry Standards

• Keros Therapeutics' net loss of $23.7 million for the quarter is within the typical range for clinical-stage biopharmaceutical companies that are heavily investing in research and development without significant product revenue.
• The company's cash burn rate, while substantial, is managed by a cash balance that provides runway into 2028, which is a critical metric for investors assessing the viability of such companies.
• The significant decrease in revenue compared to the prior year is a common occurrence for biotechs that receive large upfront payments from licensing deals, as seen with the Takeda agreement in 2025.

Legal Proceedings

• The company is not currently a party to any material arbitration or legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company needs to raise additional capital through equity offerings.
• The company's ability to continue operations and advance its product candidates impacts employees' job security and the company's future growth prospects.
• The success of the company's product candidates will impact patients seeking treatments for disorders linked to dysfunctional TGF-beta signaling.

Next Steps

• Initiate a Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in the third quarter of 2026.
• Announce initial data from the Phase 2 clinical trial of rinvatercept in patients with DMD in the first half of 2027.
• Engage with regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with amyotrophic lateral sclerosis in the second half of 2026.

Key Dates

Recommendation

The company has a strong cash position and promising pipeline candidates, but the significant net loss and reliance on future funding and clinical success warrant a cautious 'hold' rating. Investors should monitor clinical trial progress and future financing activities.

Keywords

Keros Therapeutics, Form 10-Q, Quarterly Report, Biopharmaceutical, Clinical-stage, Rinvatercept, Elritercept, Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Myelodysplastic Syndromes, Financial Results, SEC Filing